Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, Chen CS, Klag MJ, Whelton PK, He J
Researchers exploring the peptide research landscape should interpret combination protocols as rational but unproven, guided by biological plausibility rather than definitive clinical evidence
Additionally, the FDA has raised concerns specifically about compounded GLP-1 products: dosing errors, improper storage during shipping, fraudulent products, adverse event reports, and the use of semaglutide salt forms that should not be used for compounding have all been documented
GLP-1 treatment typically starts curbing appetite within 1 to 4 weeks for most beginners
Most frequent side effects of GLP-1RA were gastrointestinal effects